Skip to main content

Table 2 Association analysis of rs7044343 with RA in the discovery population

From: Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis

Characteristic ( n)

Allele frequency (%)

Genotype frequency (%)

T versus C

CC versus TT + TC

CC + TC versus TT

T

C

TT

TC

CC

OR (95% CI)

OR (95% CI)

OR (95% CI)

P value

P value

P value

Control (598)

545 (45.6)

651 (54.4)

137 (22.9)

271 (45.3)

190 (31.8)

   

RA (700)

641 (45.8)

759 (54.2)

127 (18.1)

387 (55.3)

186 (26.6)

1.009

0.777

1.354

(0.864-1.178)

(0.611-0.988)

(1.033-1.774)

0.912

0.040*

0.028*

RF + (418)

377 (45.1)

459 (54.9)

78 (18.7)

221 (52.9)

119 (28.5)

0.981

0.855

1.308

(0.822-1.172)

(0.650-1.123)

(0.958-1.785)

0.833

0.260

0.091

RF- (94)

86 (45.7)

102 (54.3)

17 (18.1)

52 (55.3)

25 (26.6)

1.007

0.778

1.359

(0.740-1.371)

(0.477-1.269)

(0.777-2.376)

0.964

0.314

0.282

ACP (300)

281 (46.8)

319 (53.2)

62 (20.7)

157 (52.3)

81 (27.0)

1.052

0.794

1.152

(0.864-1.281)

(0.584-1.080)

(0.821-1.615)

0.612

0.142

0.413

ACPA - (113)

108 (47.8)

118 (52.2)

20 (17.7)

68 (60.2)

25 (22.1)

1.093

0.610

1.395

(0.822-1.453)

(0.379-0.982)

(0.830-2.345)

0.539

0.042*

0.209

Female control (465)

432 (46.5)

498 (53.5)

106 (22.8)

220 (47.3)

139 (29.9)

   

Female RA (482)

426 (44.2)

538 (55.8)

85 (17.6)

256 (53.1)

141 (29.3)

0.913

0.970

1.396

(0.762-1.094)

(0.734-1.282)

(1.015-1.920)

0.323

0.829

0.040

Female RF+ (333)

300 (45.0)

366 (55.0)

62 (18.6)

176 (52.9)

95 (28.5)

0.945

0.936

1.306

(0.774-1.154)

(0.687-1.276)

(0.920-1.855)

0.578

0.676

0.135

Female RF- (75)

64 (42.7)

86 (57.3)

12 (16.0)

40 (53.3)

23 (30.7)

0.858

1.037

1.569

(0.606-1.215)

(0.611-1.761)

(0.816-3.018)

0.388

0.892

0.177

Female ACPA+ (243)

225 (46.3)

261 (53.7)

50 (20.6)

125 (51.4)

68 (28.0)

0.994

0.911

1.154

(0.798-1.238)

(0.647-1.285)

(0.790-1.685)

   

0.956

0.596

0.459

Female ACPA- (84)

77 (45.8)

91 (54.2)

15 (17.9)

47 (56.0)

22 (26.2)

0.975

0.832

1.375

(0.701-1.356)

(0.492-1.407)

(0.756-2.502)

0.882

0.493

0.297

Male CON (105)

99 (47.1)

111 (52.9)

26 (24.8)

47 (44.8)

32 (30.5)

   

Male RA (121)

116 (47.9)

126 (52.1)

24 (19.8)

68 (56.2)

29 (24.0)

1.032

0.719

1.330

(0.713-1.495)

(0.399-1.296)

(0.709-2.496)

0.867

0.272

0.374

Male RF+ (84)

75 (44.6)

93 (55.4)

15 (17.9)

45 (53.6)

24 (28.6)

0.904

0.913

1.514

(0.602-1.359)

(0.486-1.713)

(0.742-3.088)

0.628

0.776

0.254

Male RF- (19)

22 (57.9)

16 (42.1)

5 (26.3)

12 (63.2)

2 (10.5)

1.542

0.268

0.922

(0.767-3.100)

(0.059-1.231)

(0.303-2.805)

0.222

0.090

0.886

Male ACPA+ (57)

56 (49.1)

58 (50.9)

12 (21.1)

32 (56.1)

13 (22.8)

1.083

0.674

1.234

(0.686-1.709)

(0.320-1.420)

(0.568-2.681)

0.733

0.300

0.595

Male ACPA- (27)

29 (53.7)

25 (46.3)

5 (18.5)

19 (70.4)

3 (11.1)

1.301

0.285

1.448

(0.714-2.369)

(0.080-1.016)

(0.498-4.211)

0.390

0.053

0.497

  1. *P < 0.05 versus controls; ACPAs, anti-citrullinated proteins antibodies; CI, confidence interval.
  2. CON, healthy control; OR, odds ratio; RA, rheumatoid arthritis; RF, rheumatoid factor.